Time's wasting this morning if you haven't got BCAN on radar yet. Here's why.


Have You Seen The Breaking News On (BCAN) Yet? Today's Early Green Move Could Just Be The Start

October 24th

Greetings Readers,

Time's wasting this morning if you haven't got BCAN on radar yet. Here's why.

The company made a major announcement this morning that could help shape their future. Check it out here: Israeli Cann-a-bis Technology Company BYND Cannasoft Enterprises Inc. and Matrix Medika to Explore Further (FDA) Development of the EZ-G Device

With this announcement, the market could start paying closer attention to this Nasdaq profile that is currently flying under Wall Street's radar.

Right now, BCAN is trading above both its 5-Day Simple Moving (SMA) Average and its 5-Day Exponential Moving Average (EMA).

But with the backing of today's big news and a tiny float, it may just be a matter of time until BCAN overtakes its 20-Day SMA and 20-Day EMA which is just slightly higher than its current trading level.

If that happens, BCAN could start seeing potential support grow at those crucial areas and provide the jump start for a healthy near term reversal.

Take a moment now and read my initial report below. Then get BCAN on your watch-list immediately.


Monday's opening bell will be here quicker than you can imagine so let's dive in quickly.

I've been spectating the Nasdaq Market closely and have come across a new breakout idea.

Right now it's flying under Wall Street's radar, but who knows for how much longer...

Like many of my other hidden gems that I've delivered in October, this profile has several potential catalysts that could provide it with a near term spark.

And if this one hits the ground running like many of my alerts this month:

(10/19): Ran from an open of $.0636 to a high of $.8039 (31% intraday).

(10/13): Alerted after closing at $3.05, it ran approximately 18% to a 10/17 high of $3.62.

(10/9): Released after closing 10/7 at $.47, it moved approximately 29% to a 10/19 high of $.61.

(10/6): Brought to your attention after closing at $.88, it surged to $1.04 the following day for approximately 18%.

(10/4): Approximate 38% move during pre-market from $.60 to $.83.

... then we could be in for some serious fireworks!

So when I found out this company had just made a mind-blowing acquisition, has a freakishly low float, important October news, and key oversold leaning technicals, I knew I needed to put together this report for you ASAP.

For Monday, October 24th, there's one Nasdaq profile to get on your watch-list:

*BYND Cannasoft Enterprises Inc. (BCAN)*

BYND Cannasoft Enterprises Inc. is an integrated software/cann-a-bis company, based in Israel with a first of its kind platform for the $33Bn medical cann-a-bis market.

And right now it has 5 potential catalysts that could provide a breakout spark in the near term. Here's what to know:

No. 1 - A Crazy Low Float Could Lead To Explosive Volatility

No. 2 - A Game-Changing Acquisition That Could Help Put BCAN On The Map

No. 3 - Initial Approval Received For Cannasoft To Engage In Medical Cann-a-bis Without Direct Contact

No. 4 - Beta Test Launch For C.R.M System At Prestigious Weizmann Institute

No. 5 - Oversold Technicals Signal Bounce/Reversal Possibilities

But more on those in a second...

The Booming Cann-a-bis Market Has A New Contender

BYND Cannasoft Enterprises Inc. owns and markets a proprietary customer relationship management (CRM) software product, known as “Benefit CRM.”

BYND’s Benefit CRM software enables small and medium‐sized businesses to optimize their day‐to‐day business activities such as sales management, personnel management, marketing, call center activities and asset management.

The company's next-generation Benefit CRM platform is now ready for BETA testing.

Building on its 20 years of experience in CRM software, BYND Cannasoft Enterprises Inc. has recently begun development of an innovative new CRM platform, designed specifically to serve the needs of the medical cann-a-bis industry.

This new platform will be the first of its kind for the medical cann-a-bis field and the Company is confident it will transform the industry into a more organized, accessible, and price transparent market.

Data and information collected through the operation of the Cann-a-bis Farm and the products it produces will allow BYND to test its new Cann-a-bis CRM platform and adjust the platform as necessary.

Additionally, operating the Cann-a-bis Farm and selling medical cann-a-bis will bring in additional revenue to further support BYND during the initial roll‐out years of its cann-a-bis CRM platform.

BYND Cannasoft Enterprises Inc.'s CRM and ERP system is a state-of-the-art CRM designed with years of industry and market specific experience.

In its second generation, BYND Cannasoft Enterprises Inc. wishes to build tailored software for the cann-a-bis industry. The CRM and ERP system will be integrated into the company’s delivery and recommendation system to help manage inventory, create performance reports and financial reports.


This system gives the growers a deep insight into all aspects of managing a cann-a-bis farm and cann-a-bis distribution from the amounts of fertilizer right to managing delivery revenue – all with a few clicks. The company’s powerful BI tools allow growers to receive information in real-time, in great resolution to allow optimal efficiency and profit.

What's Next For BYND Cannasoft Enterprises Inc. (BCAN)

The Company’s plans include the construction of 4 state of the art greenhouses, housing approximately 2.5 acres of total growing area.

BYND Cannasoft Enterprises Inc. estimates that once fully operational, its Cann-a-bis farm facility will be able to produce 7,500kg of raw cann-a-bis each year.

BYND also intends to work with strategic partners to develop and market new, proprietary cann-a-bis infused products for sale throughout Israel and for export.

The company operates on 3 parallel levels as part of its plans to enter the market for growing and selling medical cann-a-bis:

  1. The company is working to transfer the initial permit for the cultivation and multiplication of medical cann-a-bis according to the partnership agreement with the Bzizinsky family, after its transfer, the company will operate for the planning and construction of a growing facility in Moshav Kochav Michael.
  2. The company has completed the planning and placement of an internal breeding facility and has applied for a growing and breeding license for this facility.
  3. The company has submitted an application for a license to trade in medical cann-a-bis “without contact with the substance” known as a constructive license, after receiving it the company will be able to implement agreements it has signed with various growers for marketing and sales of the company’s private label.

Find more key company details here.


And as I mentioned above, BCAN has 5 key potential catalysts to soak in now. Check them out:

No. 1 BCAN Potential Catalyst - A Crazy Low Float Could Lead To Explosive Volatility

According to the Yahoo Finance website, BCAN has an insanely tiny float.

The website reports this profile to have approximately 878.14k shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could more 2022 positive company news help provide a near term spark?


No. 2 BCAN Potential Catalyst - A Game-Changing Acquisition That Could Help Put BCAN On The Map

BYND Cannasoft Enterprises Inc. Signs Agreement for the Acquisition of Israeli-Based Zigi Carmel Initiatives & Investments Ltd. In a Share Swap Agreement Valued at US $28Mn

VANCOUVER, British Columbia, Sept. 18, 2022 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND” or the “Company”) announced today that it has signed a share purchase agreement to acquire 100% ownership of Zigi Carmel Initiatives & Investments Ltd. (“ZC”) which holds the patent pending intellectual property for a therapeutic device (the “EZ-G device”) that uses low concentrations of CB oils, such as hemp seed oil and other natural oils, to treat certain women's health issues...

The EZ-G device is a unique, patent-pending device that, combined with proprietary software (provisional application), regulates the flow of low-concentration CB oils into the soft tissues of the female reproductive system. According to research conducted across the globe, treatment with low-concentration CB oils can relieve candida, dryness, scars, and many other female health issues.

BYND intends to pursue the final registration of the patent and establish a marketing and sales system for the EZ-G device. The Company's ‘Go to Market’ strategic plan is based on combined B2B and B2C sales. Numerous studies have shown CB interacts with the endocann-a-binoid system, a master regulatory system with receptors all around the body. By activating these receptors, CB can have health benefits that help make sex more approachable and pleasurable by reducing stress, enhancing one's mood, promoting body comfort, and treating vaginal issues. According to the Brightfield Group, a cann-a-bis industry data research firm, sales of CB products could reach $11Bn by 2027. A recent Zion Market Research study indicates the market size of global gynecology devices was worth $10.8Bn in 2021 and is estimated to exceed $19.5Bn by 2028 with a compound annual growth rate (CAGR) of approximately 10.3 percent.


Yftah Ben Yaackov, CEO and a Director of BYND, said, "From the moment we complete the purchase of ZC, we plan to hit the ground running by initially securing any required regulatory approval from the appropriate authorities. We will continue to pursue the registration of the patent, which contains over 100 claims, prototype production and start validation tests, and contract with suppliers for the production of the device and the oils used in the EZ-G device.

The demand for a unique device combined with software, such as the EZ-G device, stems from the increasing occurrence of chronic conditions and the rising adoption of self-health management. Using a device at home is a very cost-effective treatment, and it opens up a vast channel for millions of women." Mr. Ben Yaackov continued, "We hope to use the knowledge we have gained in the medical cann-a-bis field to significantly improve the quality of life of women suffering from symptoms such as those mentioned above."

Read the full article here.


No. 3 BCAN Potential Catalyst - Initial Approval Received For Cannasoft To Engage In Medical Cann-a-bis Without Direct Contact

Israel’s Ministry of Health, through the Medical Cann-a-bis Unit, granted BYND Cannasoft Enterprises Inc.’s Subsidiary, Cannasoft an Initial Approval to Engage in Medical Cann-a-bis Without Direct Contact with the Substance

VANCOUVER, British Columbia and ASHKELON, Israel, Oct. 18, 2022 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") announced today that it received initial approval to engage in medical cann-a-bis without direct contact with the substance from the Medical Cann-a-bis Unit at the Ministry of Health of the State of Israel. Cannasoft received this initial approval as part of the process to obtain a full license that allows trading in medical cann-a-bis products through an agreement with a licensed cann-a-bis grower in Israel. Cannasoft is in the final stage of obtaining the full license.


Yftah Ben Yaackov, CEO and Director of BYND, said, "We anticipate that as long as there are no unforeseen circumstances, Cannasoft will receive a full license to engage in medical cann-a-bis without direct contact in the near future. Our strategy post-license will be to penetrate the cann-a-bis products market in Israel and globally immediately after the approval of the Israeli regulator for the export of cann-a-bis products from Israel. Our business plan allows us to accomplish this without in-vest-ing heavily in resources and establishing and operating cultivation facilities." Mr. Yaackov continued, "In this way, BYND Cannasoft will be able to realize its goal of generating significant revenues from the sale of cann-a-bis products while saving significantly on the Company's expenses for this purpose."

Read the full article here.


No. 4 BCAN Potential Catalyst - Beta Test Launch For C.R.M System At Prestigious Weizmann Institute

BYND Cannasoft Enterprises Inc. Launches Beta Test for Managing Farms CRM Platform at Israel’s Weizmann Institute of Science

VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND” or the “Company”) announced that its subsidiary BYND - Beyond Solutions Ltd. has signed an agreement with the Weizmann Institute of Science for the use of its proprietary software. ...

Yftah Ben Yaackov, CEO and a Director of BYND, said, "This is an extremely important step in the development of BYND Cannasoft Enterprises medical cann-a-bis software since the Weizmann Institute has many greenhouses of various types that can cover all the development possibilities of the software in the coming year..."


Read the full article here.


No. 5 BCAN Potential Catalyst - Oversold Technicals Signal Bounce/Reversal Possibilities

As of close Friday, Barchart was reporting this profile to have several oversold leaning technicals.

These technicals could be signaling a healthy reversal could be approaching in the near term.

Here's the definition of a "reversal" from Investopedia:

"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."

Now, here are some key technicals (as of close Friday) that could signal BCAN to be leaning oversold and on the verge of a potential reversal.

  • 9-Day Relative Strength Index: 34.67%
  • 14-Day Relative Strength Index: 34.65%

When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.

  • 20-Day Raw Stochastic: 16.66%
  • 20-Day Williams %R: 83.34%

As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.

Keep an eye on these technicals closely.


BCAN Recap - 5 Potential Breakout Catalysts To Know Before Monday's Opening Bell

No. 1 - A Crazy Low Float Could Lead To Explosive Volatility

No. 2 - A Game-Changing Acquisition That Could Help Put BCAN On The Map

No. 3 - Initial Approval Received For Cannasoft To Engage In Medical Cann-a-bis Without Direct Contact

No. 4 - Beta Test Launch For C.R.M System At Prestigious Weizmann Institute

No. 5 - Oversold Technicals Signal Bounce/Reversal Possibilities


Coverage is officially initiated on BCAN. When time permits, do this:


Get BCAN on your radar now.


Kai Parker


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading StockWireNews email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates fierceinvestor . com (“FI”), and owns and operates stockstreetwire . com ("SSW"). From time to time, StockWireNews, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Ownership of "FI" and "SSW" has now moved to a single individual. Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 10/23/22 and ending on 10/25/22 to publicly disseminate information about (BCAN) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (BCAN). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Atlanta Capital Partners LLC, TD Media LLC has been hired for a period beginning on 10/17/2022 and ending on 11/04/2022 to publicly disseminate information about (BCAN:US) (BYND:CA) via digital communications. We have been paid two hundred fifty thousand dollars USD via bank wire transfer. We own zero shares of (BCAN:US) (BYND:CA). lifewatermedia.com/bcan-disclaimer-26/